Xu Zhenyu sold $145K of SOPH
Xu Zhenyu (Chief Scientific Officer) sold 20,000 shares of SOPHiA GENETICS SA (SOPH) at an average of $7.25 ($7.00–$7.48, $0.14M total) across 3 trades over 2026-08-05 to 2026-08-07 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific sale size, price range ($7.0043 to $7.4759), and that it was executed under a pre-arranged 10b5-1 plan.
Market read
This is a routine insider sale disclosure with limited direct implications for fundamentals, but it can marginally influence short-term sentiment.
What to watch
The filing does not state whether other insiders or the company also bought shares, nor does it provide context on total insider activity or option exercises.
Background
The article is an SEC Form 4 insider transaction disclosure for SOPHiA GENETICS SA, reported by its Chief Scientific Officer.
Ticker impact
SOPHiA GENETICS CSO Xu Zhenyu sold about $145K of SOPH shares via a 10b5-1 plan, filing three trades from Aug 5-7.
Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around the filing date.
The disclosure is an open-market sale by an officer under a pre-arranged 10b5-1 plan, with no accompanying operational or financial guidance changes in the text.
Market effects
No sector-wide signal; this is company-specific insider activity with no stated regulatory or clinical catalyst.
None indicated.
None indicated.
Counterpoint
Because it is a 10b5-1 plan, the sale may reflect liquidity planning rather than bearish expectations, so traders may ignore it beyond the immediate headline.
Key entities
- issuerSOPHiA GENETICS SA
Company whose shares were sold by an officer under a 10b5-1 plan.
- insiderXu Zhenyu
Chief Scientific Officer who executed the open-market sale.
